Comparison · NCT01975519-sae
8 mg/kg TRC105 + Pazopanib vs 10 mg/kg TRC105 + Pazopanib: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 8 mg/kg TRC105 + Pazopanib vs 10 mg/kg TRC105 + Pazopanib: serious adverse events. Trial comparisons, record NCT01975519-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01975519-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0.0000000000000000555 | 0.561 | wilson | |
| Risk in group 2 | 0.0849 | 0.0453 | 0.154 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0849 | -0.154 | 0.478 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with a serious adverse event on 8 mg/kg TRC105 + Pazopanib than on 10 mg/kg TRC105 + Pazopanib | 11.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 8 mg/kg TRC105 + Pazopanib | 8 mg/kg of TRC105 in combination with standard dose pazopanib in patients with advanced soft tissue sarcoma. | 0 | 3 | EG000 |
| Group 2 | 10 mg/kg TRC105 + Pazopanib | 10 mg/kg of TRC105 in combination with standard dose pazopanib in patients with advanced soft tissue sarcoma. | 9 | 106 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse events are collected for each patient from the time of informed consent through 28 days following the last dose of study drug. Patients were eligible for participation in the trial until they progressed. The longest duration of AE collection for a given patient was 34 months.
Source ClinicalTrials.gov
Trial
- Title
- A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
- NCT number
- NCT01975519
- Phases
- PHASE1, PHASE2
- Conditions
- Advanced Soft Tissue Sarcoma
- Interventions
- TRC105 and Pazopanib
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Results first posted
- 2020-05-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01975519?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01975519-sae